JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Issues journals
Medical Radiology and Radiation Safety. 2022. Vol. 67. № 6
DOI:10.33266/1024-6177-2022-67-6-36-43
E.E. Aladova, E.K. Vasilenko , A.V. Efimov, V.V. Vostrotin, M.E. Sokolnikov, S.A. Romanov
Methodology for Rationing Internal Exposure from Plutonium: Problems and Solutions
Southern Urals Biophysics Institute, Ozersk, Russia
Contact person: E.E. Aladova, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Dedicated to E.K. Vasilenko memory
From the authors
During the last years of his life, Evgeny Konstantinovich Vasilenko worked on the most important regulatory and methodological documents on the organization and conduct of dosimetric control of internal exposure due to plutonium intake for the professional workers. He paid a special role to developing an approach to rationing the effects of plutonium compounds based on lifetime excess risk assessments. Under his leadership, several publications were published on the problem of limiting occupational exposure from the long-lived radionuclides. The presented article was prepared with the direct participation of Evgeny Konstantinovich, and it continues the series of publications he started on this problem.
We remember with gratitude Evgeny Konstantinovich Vasilenko as a wonderful scientist, creative professional and multi-talented person.
ABSTRACT
Purpose: The presented materials are devoted to the development of a methodology for rationing the impact of plutonium intake by the amount of annual excess risk, which should not exceed 1 ×10-3. It is shown that the existing approach to the rationing of plutonium by the expected effective dose does not reflect the actual levels of personnel exposure and, therefore, does not provide the necessary level of radiation safety at plutonium processing plants.
Results: Using data from epidemiological surveillance of a cohort of employees of the Mayak software, an assessment of the excessive relative risk per unit dose of radiation exposure for each of the plutonium-239 deposition organs was performed in order to describe the dependence of mortality from lung, liver and skeletal cancer on the dose of alpha radiation of plutonium-239. Equivalent doses to plutonium deposit organs and the annual excess risk generated by these doses for various plutonium intake scenarios are calculated based on the results of monitoring the activity of plutonium in urine. When calculating the annual effective dose based on the results of monitoring the annual equivalent dose, it is necessary to take into account the dependence of the weighing coefficients for the plutonium deposit bodies on the age of the employee at which the exposure occurred, and when assessing the magnitude of the radiation risk, the dependence of the risk coefficient on age.
Conclusion: The use of the annual excess risk value as a controlled and normalized indicator for the individual dosimetry control of internal radiation from the plutonium intake is the most correct. The proposed approach to rationing can be used for acute and chronic inhalation intake of plutonium, as well as for the intake of plutonium through damaged skin.
Keywords: internal exposure, plutonium, lifetime risk, dose limit, deposit organs, radiation monitoring, expected effective dose
For citation: Aladova EE, Vasilenko EK, Efimov AV, Vostrotin VV, Sokolnikov ME, Romanov SA. Methodology for Rationing Internal Exposure from Plutonium: Problems and Solutions. Medical Radiology and Radiation Safety. 2022;67(6):36–43. (In Russian).DOI:10.33266/1024-6177-2022-67-6-36-43
References
1. Radiation Safety Standards (RSS-99/2009). Sanitary-Epidemiological Rules and Standards. Moscow Publ., 2009. 100 p. (In Russ.).
2. IAEA Safety Standards Series No. GSR. Part 3. Radiation Protection and Safety of Radiation Sources: International Basic Safety Standards. Vienna, 2011. 303 p.
3. ICRP, 2007. Recommendations of the International Commission on Radiological Protection. ICRP. Publication 103. Ann. ICRP. 2007;37;2-4:1-332.
4. Koshurnikova N.A., Shilnikova N.S., Okatenko P.V., Kreslov V.V., Bolotnikova M.G., Sokolnikov M.E., Khokhriakov V.F., Suslova K.G., Vassilenko E.K., Romanov S.A. Characteristics of the Cohort of Workers at the Mayak Nuclear Complex. Radiat. Res. 1999;152:352-363.
5. Sokolnikov M., Preston D., Gilbert E., Schonfeld S., Koshurnikova N. Radiation Effects on Mortality from Solid Cancers other than Lung, Liver, and Bone Cancer in the Mayak Worker Cohort: 1948-2008. PLoS One. 2015;10:e0117784.
6. Sokolnikov M.E., Gilbert E.S., Preston D.L., Ron E., Shilnikova N.S., Khokhryakov V.V., Vasilenko E.K., Koshurnikova N.A. Lung, Liver and Bone Cancer Mortality in Mayak Workers // Int. J. Cancer. 2008. No. 123. P. 905-911.
7. Koshurnikova N.A., Gilbert E.S., Sokolnikov M., Khokhryakov V.F., Miller S., Preston D.L., Romanov S.A., Shilnikova N.S., Suslova K.G., Vostrotin V.V. Bone Cancers in Mayak Workers. Radiat. Res. 2000;154:237-245.
8. Gilbert E.S., Koshurnikova N.A., Sokolnikov M., Khokhryakov V.F., Miller S., Preston D.L., Romanov S.A., Shilnikova N.S., Suslova K.G., Vostrotin V.V. Liver Cancers in Mayak Workers. Radiat. Res. 2000;154:246-252.
9. Gilbert E.S., Sokolnikov M., Preston D.L., Schonfeld S.J., Schadilov A.E., Vasilenko E.K., Koshurnikova N.A. Lung Cancer Risks from Plutonium: an Updated Analysis of Data from the Mayak Worker Cohort. Radiat. Res. 2013;179:332-342.
10. Preston D.L., Lubin J.H., Pierce D.A., McConney M.E. Epicure Users Guide. Seattle, Washington, Hirosoft International Corporation, 1993.
11. Thomas D., Darby S., Fagnani F., Hubert P., Vaeth M., Weiss K. Definition and Estimation of Lifetime Detriment from Radiation Exposures: Principles and Methods. Health Physics. 1992;63:259-272.
12. Khokhryakov V.V., Khokhryakov V.F., Suslova K.G., Vostrotin V.V., Vvedensky V.E., Sokolova A.B., Krahenbuhl M.P., Birchall A., Miller S., Schadilov A.E., Ephimov A.V. Mayak Worker Dosimetry System 2008 (MWDS-2008): Assessment of Internal Dose from Measurement Results of Plutonium Activity in Urine. Health Phys. 2013;104:366-378.
13. Development of a Biokinetic Model for Radionuclide-Contaminated Wounds and Procedures for their Assessment, Dosimetry and Treatment: Recommendation of the Nationale Counsil on Radiation Protection and Measurements. NCRP Report No. 156. NCRP. 2007. 411 p.
14. Shchadilov A.Ye. Monitoring for Actinide Intakes Through Injured Skin in Mayak PA Workers. Istochniki i Effekty Oblucheniya Rabotnikov PO «Mayak» i Naseleniya, Prozhivayushchego v Zone Vliyaniya Predpriyatiya = Radioactive Sources and Radiation Effects on the Mayak PA Workers and Population Living in the Area of Nuclear Facility Influence. Collection of SUBI writings. Ozyorsk Publ. 2009. P. 94-126 (In Russ.).
15. ICRP, 1994. Human Respiratory Tract Model for Radiological Protection. ICRP Publication 66. Ann. ICRP. 1994;24;1-3.
16. Vasilenko Ye.K., Sokolnikov M.E., Vostrotin V.V., Yefimov A.V., Aladova Ye.Ye., Romanov S.A. Limiting Occupational Exposure Due to Plutonium Inhalation Intake. Radiatsiya i Risk = Radiation and Risk. 2015;24;3:51-58 (In Russ.).
17. Sokolnikov M.E., Vasilenko Ye.K., Yurkin A.M., Vostrotin V.V., Yefimov A.V., Aladova Ye.Ye. Limit on Intake of 239Pu in a Human Body Through Wound. Radiatsiya i Risk = Radiation and Risk. 2016;25;2:109-117 (In Russ.).
18. Sokolnikov M.E., Vostrotin V.V., Yefimov A.V., Vasilenko Ye.K., Romanov S.A. Estimates of Lifetime Risk of Lung Cancer Death Under Different Scenarios of 239Pu Inhalation. Radiatsiya i Risk = Radiation and Risk. 2015;24;3:59-70 (In Russ.).
19. ICRP, 1991. 1990 Recommendations of the International Commission on Radiological Protection. ICRP. Publication 60. Ann. ICRP. 1991;21;1-3.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The work was carried out within the framework of state contract No. 11.306.22.2 «Solving of the relevant issues of internal dosimetry for personnel and population» (code «Radiometry-22»), funded by the FMBA of Russia.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.07.2022. Accepted for publication: 25.09.2022.
Medical Radiology and Radiation Safety. 2022. Vol. 67. № 6
DOI:10.33266/1024-6177-2022-67-6-44-50
M.L. Belyanin1, A.S. Podyablonsky1, 2, O.Yu. Borodin1, 2, 3, M.V. Belousov3,
E.N. Karpov2, V.D. Filimonov1, N.L. Shimanovskii4, W.Yu. Ussov1, 5
Synthesis and Preclinical Evaluation of Imaging Abilities of 99mТс-DTPA-GDOF
as a New Original Russian Hepatotropic Agent for Scintigraphy and SPECT Studies
1National Research Tomsk Polytechnic University, Tomsk, Russia
2Tomsk Regional Oncology Center, Tomsk, Russia
3Siberian State Medical University, Tomsk, Russia
4 N.I. Pirogov Russian National Research Medical University, Moscow, Russia
5Cardiology Research Institute, Tomsk National Research Medical Center, Tomsk, Russia
Contact person: Wladimir Yurievich Ussov, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: Was to obtain a radiopharmaceutical (RPH) ‒ 99mTc bound with DTPA-GDOF (2-(2-carboxymethyl-(4-hexa-decyloxyphenyl-carbamoyl-methyl)-aminoethyl)-aminoethyl-(4-hexadecyl-oxyphenyl-carbamoyl methyl)-aminoacetic acid) and evaluate in an in vivo experiment on laboratory rats the possibility of using as hepatotropic RPH for scintigraphy and SPECT.
Material and methods: The synthesis of DTPA-GDOF was carried out according to the original method of M.L. Belyanin e.a. at the N.M. Kizhner Center of TPU, by the interaction of 4-hexadecyloxyaniline with diethylenetriaminopentaacetic acid (d-DTPA) anhydride in dimethylformamide medium. Then 2 mg of GDOF-DTPA powder was mixed with 0.5 ml of
5 % sodium bicarbonate solution and heated to 100 oC until completely dissolved. 2 mg of tin dichloride powder were added to the solution, stirred and incubated at 25 oC for at least 20 minutes. The resulting solution was mixed with 99mTc eluate with an activity of 3 MBq and incubated for 10 min at 25 oC. Control of the labelling efficiency of 99mTc with DTPA-GDOF was carried out by chromatography on paper, according to the method of Zimmer and Pavel (1977).
An in vivo study of the absorption kinetics of 99mTc-DTPA-GDOF was performed on male rats of the Wistar line
(n = 12) 300–350 g. 99mTc-DTPA-GDOF at a dosage of 0.025 mmol/kg, 3 MBq was injected into the femoral vein. All scans are performed using the SPECT/CT Siemens Symbia T. Dynamic planar study included recording 4 sec/frame for the first two minutes, 128 × 128 pixels, and then up to 20 min – as 15 s/frame, followed by a SPECT/CT of the whole body. The value of the fraction of extraction (retention) of RPH in the liver was calculated. The values of the organ accumulation of RPH were determined as the organ fraction of uptake of the agent relative to the total dose administered to the animal
Results. The labeling efficiency of DTPA-GDOF with 99mTc in fresh eluate of a standard molybdenum generator was in all cases more than 94 % (on average 95.6 ± 2.1 %, thus the proportion of free technetium was up to 4‒4.5 %). When storing 99mTc-DTPA-GDOF at room temperature on a shelf for up to 5 hours, the release of 99mTc-from the complex with DTPA-GDOF did not exceed 3.1 ± 0.3 %. The extraction fraction of 99mTc-DTPA-GDOF in the liver is as high as 0.78 ± 0.04. The fraction of the injected dose taken up by the liver is up to 70 % (68.9 ± 8.9). The quota of the spleen uptake is 14.1 ± 4.2 %. The level of accumulation of 99mTc-DTPA-GDOF in the liver was then maintained steadily without a significant decrease for up to 16‒18 hours.
Conclusion: The 99mTc-DTPA-GDOF complex is a original RFP, with a high 99mTc labeling efficiency, long-lasting stability after labelling, and providing in vivo highly specific long-term imaging of the liver and spleen with gamma scintigraphy and SPECT.
Keywords: liver, 99mTc-DTPA-GDOF, SPECT, Technetium–99m, radiopharmaceuticals, rats
For citation: Belyanin ML, Podyablonsky AS, Borodin OYu, Belousov MV, Karpov EN, Filimonov VD, Shimanovskii NL, Ussov WYu. Synthesis and Preclinical Evaluation of Imaging Abilities of 99mТс-DTPA-GDOF as a New Original Russian Hepatotropic Agent for Scintigraphy and SPECT Studies. Medical Radiology and Radiation Safety. 2022;67(6):44–50. (In Russian). DOI:10.33266/1024-6177-2022-67-6-44-50
References
1. Shabunin A.V., Karalkin A.V., Grekov D.N., Drozdov P.A. Hybrid Technology in Determination of Functioning Volume of Liver Before Major Resections. Meditsinskaya Vizualizatsiya = Medical Visualization. 2015;4:39-45 (In Russ.).
2. Samoylov A.S., Kodina G.Ye., Larenkov A.A. Design and Implementation of New Types of Radiopharmaceuticals. Meditsina: Tselevyye Proyekty. 2015;20:19-22 (In Russ.).
3. Kodina G.Ye., Kulakov V.N., Sheyno I.N. Rare Earth Elements in Nuclear Medicine (Review). Saratovskiy Nauchno-Meditsinskiy Zhurnal = Saratov Journal of Medical Scientific Research. 2014;10;4:849–858 (In Russ.).
4. Sannikov M.Yu., Borodin O.Yu., Belyanin M.L., Semichev Ye.V., Bushlanov P.S., Filimonov V.D., et al. Preclinical Evavaluation of GDOF-Mn-DTPA as Contrast Media Versus Gd-EOB-DTPA for Contrast Enhanced Magnetic Resonance Imaging . Izvestiya Vysshih Uchebnyh Zavedeniy. Fizika. 2015;58;12-2:79-84 (In Russ.).
5. Podyablonskiy A.S., Belyanin M.L., Borodin O.Yu., Belousov M.V., Brazovskiy K.S., Krivoshchekov S.V., et al. Paramagnetic Contrast Enhancement in MRI Imaging of Liver Using an Original Hepatotropic High-Affinity Agent GDOF-Mn-DTPA. Translyatsionnaya Meditsina = Translational Medicine. 2021;8;2:14-22. DOI 10.18705/2311-4495-2020-8-2-14-22 (In Russ.).
6. Usov V.Yu., Belyanin M.L., Filimonov V.D., Danilets M., Milto I.V., Vesnina Zh.V., et al. Theoretical Basis and Experimental Study of Complex of Manganese (II) with Haxamthyl Propilenamin-Oxime as Paramagnetic Contrast Agent for MR-Imaging of Malignant Tumors. Luchevaya Diagnostika i Terapiya = Diagnostic Radiology and Radiotherapy. 2019;2;10:42-49. DOI: 10.22328/2079-5343-2019-10-2-42-49 (In Russ.).
7. Usov V.Yu., Belyanin M.L., Churin A.A., Bezlepkin A.I., Borodin O.Yu., Zorkaltsev M.A., et al. Trans-1.2-Diaminocyclohexan-N,N,N’,N’-Tetraacetic Acid (DCTA) as Multimodal Chelator for MRI and Single Photon Emission Imaging Using Complexes with Mn(Cyclomang) and 99mTc (Cyclotech). Diagnosticheskaya i Interventsionnaya Radiologiya = Diagnostic and Interventional Radiology. 2020;14;3:91-100. DOI 10.25512/DIR.2020.14.3.10 (In Russ.).
8. Usov V.Yu., Filimonov V.D., Belyanin M.L., Bezlepkin A.I., Luchich M.A., Kovalenko A.Yu., et al. Synthesis, Quantum Chemistry Analysis and Pre-Clinical in Vivo Evaluation of Magnetic Resonance Imaging Abilities of Paramagnetic Manganese Complex with 2,3-Dimercaptosucinate (Succimang). Meditsinskaya Vizualizatsiya = Medical Visualization. 2019;23;3:133-143. DOI 10.24835/1607-0763-2019-3-133-143 (In Russ.).
9. Zimmer A.M., Pavel D.G. Rapid Miniaturized Chromatographic Quality Control Procedures for Tc-99m Radlopharmaceuticais. J. nucl. Med. 1977;18:1230-1233.
10. Bondareva I.B., Narkevich B.Ya. Identification of Radiopharmaceutical Transport Models in Functional Radionuclide Diagnosis. Мedical Radiology. 1991;36;5:36-39.
11. Touya J.J., Rahimian J., Grubbs D.E., Corbus H.F., Bennett L.R. A Noninvasive procedure for In Vivo Assay of a Lung Amine Endothelial Receptor. J. Nucl. Med. 1985;26:1302-1307.
12. Velichko S.A., Slonimskaya Ye.M., Ryannel Yu.E. Scintigraphic Assessment of Local 99mTc-MIBI Uptake in Breast Cancer. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost = Medical Radiology and Radiation Safety. 1996;41;4:39-44 (In Russ.).
13. Panov V.O., Shimanovskiy N.L. Has the Stability of Gadolinium-Based Magnetic Resonance Contrast Media the Clinical Significance? Vestnik Rentgenologii i Radiologii = Journal of Radiology and Nuclear Medicine. 2016;97;4:243-256
(In Russ.).
14. Lindner T., Altmann A., Krämer S., Kleist C., Loktev A., Kratochwil C., et al. Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy. J. Nucl. Med. 2020;61;10:1507-1513. doi: 10.2967/jnumed.119.239731.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The research was carried out with the support of RFBR Grant No. 20-315-90114.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.07.2022. Accepted for publication: 25.09.2022.
Medical Radiology and Radiation Safety. 2022. Vol. 67. № 6
DOI:10.33266/1024-6177-2022-67-6-62-66
G.G. Shimchuk1, A.B. Bruskin2, Gr.G. Shimchuk1
Opportunities and Prospects for Russia to Create Pet Centers Based on Generator Radionuclides
1 National Research Center “Kurchatov Institute”, Moscow, Russia
2 A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia
Contact person: G.G. Shimchuk, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
An assessment of the capabilities of generator radionuclides and a list of generator pairs of radionuclides whose daughter isotope has the potential to be used in medicine for PET research is given. A list of typical 68Ga-based PET radiopharmaceuticals for oncology studied in preclinical and clinical studies is provided. Data on the use of the 82Sr/82Rb generator in clinical diagnostics are presented. The assessment of the existing situation with PET centers in Russia is given. A strategy for the development of a network of clinical PET centers and an overview of the state of generator technologies in Russia are proposed.
This article concludes that the use of generators makes it possible to significantly expand the range of clinical institutions capable of providing PET diagnostics and conducting PET studies, having only 1 or several PET scanners in the clinic. It is concluded that due to a serious reduction in capital investments (by 1.5 times) and a noticeable reduction in the cost of operation (by 1.5‒2 times), the use of generator systems will significantly reduce the cost of many PET diagnostic procedures in oncology and cardiology, make this method more accessible to a wide range of the country’s population.
Keywords: PET center, radionuclide generator, generator technologies, generator radiopharmaceuticals for PET.
For citation: Shimchuk GG, Bruskin AB, Shimchuk GrG. Opportunities and Prospects for Russia to Create Pet Centers Based on Generator Radionuclides. Medical Radiology and Radiation Safety. 2022;67(6):62–66. (In Russian). DOI:10.33266/1024-6177-2022-67-6-62-66
References
1. Green M.W., Tucker W.D. An Improved Gallium-68 Cow. J. Appl. Radiat. Isotop. 1961;12:62–64.
2. Yano Y., Anger H.O. A Gallium-68 Positron Cow for Medical Use. J. Nucl. Med. 1964;5:484–487.
3. Rösch F. 68Ge/68Ga Generators: Past, Present and Future. Theranotics, Gallium-68, and Other Radionuclides. Springer, 2012. P. 3–16.
4. Maecke H.R., André J.P. 68Ga-PET Radiopharmacy: A Generator-Based Alternative to 18F-Radiopharmacy. Ernst. Schering Res. Found Workshop. 2007;62:215-242. doi: 10.1007/978-3-540-49527-7_8.
5. Lau J., Rousseau E., Kwon D., Lin K.-S., Bénard F., Chen X. Insight into the Development of PET Radiopharmaceuticals for Oncology. Cancers. 2020;12;5:1312.
6. Rangger C., Haubner R. Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology. Pharmaceuticals. 2020;13:22.
7. Weineisen M., Schottelius M., Simecek J. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J. Nucl. Med. 2015;56;8:1169-1176. doi: 10.2967/jnumed.115.158550.
8. Wunderlich G., Schiller E., Bergmann R., Pietzsch H.J. Comparison of the Stability of Y-90-, Lu-177- and Ga-68- Labeled Human Serum Albumin Microspheres (DOTA-HSAM). Nucl. Med. Biol. 2010;37;8:861-867. doi: 10.1016/j.nucmedbio.2010.05.004.
9. Li L., Chen X., Yu J., Yuan S. Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors. Front. Oncol. 2022;12:837952. doi: 10.3389/fonc.2022.837952.
10. Grönman M., Tarkia M., Kiviniemi T., et al. Imaging of αvβ3 Integrin Expression in Experimental Myocardial Ischemia with [68Ga]NODAGA-RGD Positron Emission Tomography. J. Transl. Med. 2017;15;1:144. doi: 10.1186/s12967-017-1245-1.
11. Gould K.L. Clinical Cardiac PET Using Generator-Produced Rb-82: a Review. Cardiovasc Intervent Radiol. 1989;12;5:245-251. doi: 10.1007/BF02575408.
12. Saha G.B., MacIntyre W.J., Go R.T. Radiopharmaceuticals for Brain Imaging. Semin. Nucl. Med. 1994;24;4:324-349. doi: 10.1016/s0001-2998(05)80022-4.
13. Slosman D.O., Spiliopoulos A., Keller A., et al. Quantitative Metabolic PET Imaging of a Plasma Cell Granuloma. J. Thorac. Imaging. Spring. 1994;9;2:116-119. doi: 10.1097/00005382-199421000-00013.
14. Чудаков В.М., Жуйков Б.Л., Ермолаев С.В. и др. Исследование характеристик генератора 82Rb для позитронно-эмиссионной томографии // Радиохимия. 2014. Т.56, № 5. С. 445-461. [Chudakov V.M., Zhuykov B.L., Yermolayev S.V., et al. Characterization of a 82rb Generator for Positron Emission Tomography. Radiokhimiya = Radiochemistry. 2014;56;5: 445-461 (In Russ.)].
15. Шимчук Г.Г., Шимчук Гр.Г., Кутузов С.Г. и др. Автоматизированная генераторная система клинического применения для болюсных и продолжительных инъекций хлорида Rb-82 // Медицинская физика. 2013. № 2. С. 67-75. [Shimchuk G.G., Shimchuk Gr.G., Kutuzov S.G., et al. The Automated Generator System of Clinical Application for Bolus and Continual Infusion of Rb-82 Chloride. Meditsinskaya Fizika = Medical Physics. 2013;2:67-75 (In Russ.)].
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The work was carried out with the support of the SIC «Kurchatov Institute» (Order No. 2751 dated 28.10.2021).
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.07.2022. Accepted for publication: 25.09.2022.
Medical Radiology and Radiation Safety. 2022. Vol. 67. № 6
DOI:10.33266/1024-6177-2022-67-6-51-61
N.V. Denisova
Computational Phantoms for Medical Radiology
S.A. Khristianovich Institute of Theoretical and Applied Mechanics, Novosibirsk, Russia
Novosibirsk State University, Novosibirsk, Russia
Contact person: N.V. Denisova, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
This paper provides a brief overview of the computational anthropomorphic phantoms development for research in medical imaging, radiation dosimetry and radiotherapy planning. In medical radiology, clinical research methods are limited due to the radiation exposure of patients, volunteers and researchers, so great efforts are directed to the development of a mathematical modeling method. Computational phantoms are used in simulation as virtual patients. This new way of research in medicine opens up huge opportunities in the development of high technologies. Over the past decade, several leading groups have formed in the world that have licensed families of named anthropomorphic phantoms for radiation dosimetry and radiation therapy. The review considers the work of almost all major developers of computational phantoms in the world and in Russia. Particular attention is paid to the development of computational phantoms for research in the field of medical imaging (SPECT, PET).
Keywords: nuclear medicine, computational anthropomorphic phantoms, mathematical modeling
For citation: Denisova NV. Computational Phantoms for Medical Radiology. Medical Radiology and Radiation Safety. 2022;67(6):51–61. (In Russian). DOI:10.33266/1024-6177-2022-67-6-51-61
References
1. Rumyantsev P.O., Trukhin A.A., Sergunova K.A., Sirota Ya.I., Makarova N.M., Bubnov A.A., Semenov D.S., Akhmad Ye.S. Phantoms for Nuсlear Medicine. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost = Medical Radiology and Radiation Safety. 2020;65;2:62–67 (In Russ.).
2. Haydel L. Moore 3d Prints First Full ‘Human’ For Radiation Therapy Research. Louisiana State University. 2018.
3. Xu X.G. An Exponential Growth of Computational Phantom Research in Radiation Protection, Imaging, and Radiotherapy: a Review of the Fifty-Year History. Phys. Med. Biol. 2014;59;18:R233-302. doi: 10.1088/0031-9155/59/18/R233.
4. Kainz W., Neufeld E., Bolch W.E., Graff C.G., Chan Hyeong Kim, Niels Kuster, Bryn Lloyd, Tina Morrison, Paul Segars, Yeon Soo Yeom, Maria Zankl, Xu X. George, Benjamin M.W. Tsui. Advances in Computational Human Phantoms and Their Applications in Biomedical Engineering—A Topical Review. IEEE Trans. Rad. Plasma Med. Sci. 2019;3;1:1-23.
5. Handbook of Anatomical Models for Radiation Dosimetry (Series in Medical Physics and Biomedical Engineering). Ed. Xu X. George, Keith F. Eckerman. CRC Press, 2009. ISBN 9781420059793.
6. Fisher H.L.J., Snyder W.S. 1966 Variation of Dose Delivered by 137Cs as a Function of Body Size from Infancy to Adulthood. Health Physics Division Annual Progress Report for Period Ending July 31, 1966. Oak Ridge National Laboratory. 1966. 221–228.
7. Billings M.P., Yucker W.R. The Computerized Anatomical Man (CAM) model NASA CR-134043. Houston, TX, National Aeronautics and Space Administration, 1973.
8. Kramer R., Zankl M., Williams G., Drexler G. The male (ADAM) and Female (EVA) Adult Mathematical Phantoms GSF-Report S-885. The Calculation of Dose from External Photon Exposures Using Reference Human Phantoms and Monte Carlo Methods. Part I. Neuherberg: Institut Fuer Strahlenschutz, GSF-Forschungszentrum Fuer Umwelt und Gesundheit, 1982.
9. Tsui B.M., Terry J.A., Gullberg G.T. Evaluation of Cardiac Cone-Beam Single Photon Emission Computed Tomography Using Observer Performance Experiments and Receiver Operating Characteristic Analysis. Inv. Radiol. 1993;28:1101–1112.
10. Pretorius P.H., Xia W., King M.A., Tsui B.M., Pan T.S., Villegas B.J. Evaluation of Right and Left Ventricular Volume and Ejection Fraction Using A Mathematical Cardiac Torso Phantom. J. Nucl. Med. 1997;38:1528–1535.
11. Park S., Lee J.K., Lee C. Development of a Korean Adult Male Computational Phantom For Internal Dosimetry Calculation. Radiat. Prot. Dosim. 2006;121:257–264.
12. Hirata A., Ito N., Fujiwara O., Nagaoka T., Watanabe S. Conservative Estimation of Whole-Body-Averaged SARs in Infants with a Homogeneous and Simple-Shaped Phantom in the GHz Region. Phys. Med. Biol. 2008;53:7215–7223.
13. Qiu R., Li J., Zhang Z., Wu Z., Zeng Z., Fan J. Photon SAF Calculation Based on the Chinese Mathematical Phantom and Comparison with the ORNL Phantoms. Health. Phys. 2008;95:716–724.
14. Yevseyenko L.V., Kurakin A.A., Tultayev A.V., Chernyayev A.P. Matematicheskaya Model Fantoma Cheloveka v Radionuklidnoy Diagnostike i Terapii = Mathematical Model of a Human Phantom in Radionuclide Diagnostics and Therapy. Moscow Publ., 2002. P. 1–62 (In Russ.).
15. Denisova N.V., Kurbatov V.P., Terekhov I.N. Development of a mathematical phantom for modeling the procedure for examining patients using SPECT in cardiology. Meditsinskaya Fizika = Medical Physics. 2014;2:55-62 (In Russ.).
16. Denisova N., Ondar M., Hunor Kertesz, Thomas Beyer. Development of Anthropomorphic Mathematical Phantoms for Simulations of Clinical Cases in Diagnostic Nuclear Medicine. Computer Methods in Biomechanics and Biomedical Engineering: Imaging & Visualization. 2022. DOI: 10.1080/21681163.2022.2074308.
17. Denisova N.V., Ansheles A.A. A Study of False Apical Defects in Myocardial Perfusion Imaging with SPECT/CT. Biomed. Phys. Eng. Express. 2018;4:065018.
18. Denisova N.V., Ansheles A.A., Sergienko V., Kertész H., Beyer T., Kolinko I. Artefacts Reduction in Cardiac SPECT Images by Using a Novel Reconstruction Algorithm Maximum a Posteriori with Local Regularization. EJNMMI. 2019.;46;Suppl 1:S62-S63.
19. Denisova N., Kertész H., Beyer T. Local Statistical Regularization Method for Solving Image Reconstruction Problems in Emission Tomography with Poisson Data. AIP Conference Proceedings. 2021;2351;1. https://doi.org/10.1063/5.0052104.
20. Williams G., Zankl M., Abmayr W., Veit R., Drexler G. The Calculation of Dose from External Photon Exposures Using Reference and Realistic Human Phantoms and Monte Carlo Methods. Phys. Med. Biol. 1986;31:449–452.
21. Petoussi-Henss N., Zankl M., Fill U., Regulla D. The GSF Family of Voxel Phantoms. Phys. Med. Biol. 2002;47:89–106.
22. Zankl M., Veit R., Williams G., et al. The Construction of Computer Tomographic Phantoms and Their Application in Radiology and Radiation Protection. Radiat. Environ. Biophys. 1988;27:153–164.
23. Zankl M., Wittmann A. The Adult Male Voxel Model ‘GOLEM’ Segmented from Whole-Body CT Patient Data. Radiat Environ Biophys. 2001;40:153-162.
24. ICRP, 2009. Adult Reference Computational Phantoms. ICRP Publication 110. Ann. ICRP. 2009;39;2.
25. Zankl M., Eakins J., Goméz-Ros J.M., Huet C., Jansen J.T.M., Moraleda M., Reichelt U., Struelens L., Vrba T. EURADOS Intercomparison on the Usage of the ICRP/ICRU Adult Reference Computational Phantoms. Radiation Measurements. 2021;145;106596:1-5. https://doi.org/10.1016/j.radmeas.2021.106596.
26. Zubal I.G., Harrell C.K., Smith E.O., Kattner Z., Gindi G., Hoffer P.B. Computerized Threedimensional Segmented Human Anatomy. Med. Phys. 1994;21:299-302.
27. Zubal I.G., Harrell C.R., Smith E.O., Smith A.L. Two Dedicated Software, Voxel-Based, Anthropomorphic (Torso And Head) Phantoms. Voxel phantom development, 6 and 7 July 1995, Chilton, UK. 1995. P. 105-111.
28. Xu X.G., Chao T.C., Bozkurt A. VIP-Man: An Image-Based Whole-Body Adult Male Model Constructed from Color Photographs of the Visible Human Project for Multi-Particle Monte Carlo Calculations. Health Phys. 2000;78:476–486.
29. Wang B., Xu X.G., Kim C.H. A Monte Carlo CT Model of the Rando Phantom. Trans. Am. Nucl. Soc. 2004;90:473–474.
30. Nipper J.C., Williams J.L., Bolch W.E. Creation of Two Tomographic Voxel Models of Paediatric Patients in the First Year of Life. Phys. Med. Biol. 2002;47:3143–3164.
31. Lee C., Lee J., Lee C. Korean Adult Male Voxel Model KORMAN Segmented from Magnetic Resonance Images. Med. Phys. 2004;31;5:1017–1022.
32. Saito K., Wittmann A., Koga S., Ida Y., Kamei T., Funabiki J., Zankl M. Construction of a Computed Tomographic Phantom for a Japanese Male Adult and Dose Calculation System. Radiat. Environ. Biophys. 2001;40:69–75.
33. Zhang B., Ma J., Liu L., Cheng J. CNMAN: A Chinese Adult Male Voxel Phantom Constructed from Color Photographs of a Visible Anatomical Data Set. Radiat. Prot. Dosimetry. 2007;124;2:130–136.
34. URL: https://visiblehumanproject.com/.
35. Shevchenko Yu.L., Karpov O.E., Bronov O.Yu. Pirogov sections as a forerunner of modern computed tomography. Vestnik Natsionalnogo Mediko-Khirurgicheskogo Tsentra im. N.I. Pirogova = Bulletin of Pirogov National Medical & Surgical Centre. 2020;15;3:11-15. https://doi.org/10.25881/BPNMSC.2020.90.47.002 (In Russ.).
36. Moiseyenko D.N., Kurachenko Yu.A. Voxel Phantoms in Problems of Medical Physics. Meditsinskaya Fizika = Medical Physics. 2012;3:27 (In Russ.).
37. Moiseyenko D.N. Dissertation abstract. 2013 (In Russ.).
38. Medzhadzh T., Ksenofontova A.I., Dalechina A.V. Creating a Voxel Phantom for Dosimetric Verification of Treatment Plans in the Gamma-Knife Perfexion Using the Monte Carlo Method. Vestnik Natsionalnogo Issledovatelskogo Yadernogo Universiteta “MIFI”. 2019;8;5:473-479. doi: 10.1134/S2304487X19050055 (In Russ.).
39. Segars W.P. Development and Application of the New Dynamic NURBS-Based Cardiac-Torso (NCAT) Phantom. Chapel Hill, NC, University of North Carolina, 2001.
40. Segars W.P., Sturgeon G., Mendonca S., Grimes J., Tsui B.M.W. 4D XCAT Phantom for Multimodality Imaging Research. Med. Phys. 2010;37;9:4902-4915.
41. Segars W.P., Tsui B.M.W. MCAT to XCAT: the Evolution of 4D Computerized Phantoms for Imaging Research. Proc. IEEE Inst. Electr. Electron Eng. 2009;97;12:1954-1968.
42. Segars W.P., Tsui B.M.W., Jing Cai, Fang-Fang Yin, Fung GSK, Samei E. Application of the 4-D XCAT Phantoms in Biomedical Imaging and Beyond. IEEE Trans. Med. Imaging. 2018;37;3:680-692. doi: 10.1109/TMI.2017.2738448.
43. Abadi E., Segars W.P., Tsui B.M.W., Kinahan P.E., Bottenus N., Frangi A.F., Maidment A., Lo J., Samei E. Virtual Clinical Trials in Medical Imaging: a Review. J. Med. Imaging (Bellingham). 2020;7;4:042805. doi: 10.1117/1.JMI.7.4.042805.
44. Xu X.G. Computational Phantoms for Radiation Dosimetry: A 40-Year History of Evolution. Handbook of Anatomical Models for Radiation Dosimetry. Ed. Xu X.G., Eckerman K.F. Boca Raton, FL, Taylor & Francis, 2009. P. 3–42.
45. Lee C., Lodwick D., Hasenauer D.,Williams J.L., Lee C., Bolch W.E. Hybrid Computational Phantoms of the Male and Female Newborn Patient: NURBS-Based Whole-Body Models. Phys. Med. Biol. 2007;52:3309–3333.
46. Kim C.H., Jeong J.H., Bolch W.E., Cho K.-W., Hwang S.B. A Polygon-Surface Reference Korean Male Phantom (PSRK-Man) and Its Direct Implementation in Geant4 Monte Carlo Simulation. Phys. Med. Biol. 2011;56:3137–3161.
47. Farah J., Broggio D., Franck D. Examples of Mesh and NURBS Modelling for in Vivo Lung Counting Studies. Radiat. Prot. Dosimetry. 2011;144:344–348.
48. Christ A., et al. The Virtual Family—Development of Surface-Based Anatomical Models of Two Adults and Two Children for Dosimetric Simulations. Phys. Med. Biol. 2010;55:N23–N38.
49. ICRP. Adult Mesh-Type Reference Computational Phantoms. ICRP Publication 145. Ann. ICRP. 2020;49;3.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.07.2022. Accepted for publication: 25.09.2022.
Medical Radiology and Radiation Safety. 2022. Vol. 67. № 6
DOI:10.33266/1024-6177-2022-67-6-67-73
I.D. Rozanov1, M.S. Bunak2, A.A. Glazkov2, E.A. Stepanova2, S.S. Lebedev1, A.S. Balkanov2
Postoperative Perfusion Magnetic Resonance Imaging as a Tool
for Predicting Survival in Glioblastoma of the Brain
1S.P. Botkin City Clinical Hospital, Outpatient Cancer Care Center, Moscow, Russia
2M.F. VladimirskyMoscow Regional Research Clinical Institute, Moscow, Russia
Contact person: Andrey Sergeevich Balkanov, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Glioblastoma is the most frequently detected primary brain tumor (pGB), the prognosis of which significantly depends on the magnitude of residual GB (rGB), for which magnetic resonance imaging (MRI) is used in the postoperative period.
Purpose: To analyze the data of ASL perfusion MRI (ASL-pMRI) performed prior to adjuvant radiation therapy (aRT), 6 to 8 weeks after resection of pGB, in terms of their prognostic significance for survival in this group of patients.
Material and methods: The study included 54 patients (median age ‒ 58 years; gender: 29 men, 25 women). The Karnovsky index in
81.5 % of patients was ≥80 %. To visualize and calculate the dimensions of the rGB, ASL-pMRI was used according to the type of pseudo-continuous three-dimensional marking of arterial spins. The focus/foci of hyperperfusion (CBFmean > 64 ml/100g/min) in the area of the wall of the postoperative cyst were considered as rGB.
Results: Survival in the total group of 54 patients with pGB was 18 months (95 % CI:14.23) . The use of ASL-pMRI made it possible to visualize rGB in 37 (68.5 %) patients. The probability of visualization of rGB was significantly higher (p=0.02) in the case of temporal localization of the tumor. Age (HR:1.04; 95 % CI: 1.01‒1.07; p=0.007), the maximum diameter of the rGB (HR:1.04; 95 % CI: (1.01‒1.07); p=0.03) and localization of pGB in the temporal lobe (HR:2.00; 95 % CI: 1.05‒3.80; p=0.034) had a significant negative impact on survival. The use of the multifactorial Cox model showed that only the age ≥60 years (HR:2.78; 95 % CI:1.26‒6.15; p=0.012) and the maximum diameter of rGB ≥25 mm (HR:3.35; 95 % CI:1.36‒8.22; p=0.008) retained their significant negative impact on the survival of patients with pGB.
Conclusions: the use of ASL – pMRI 6 to 8 weeks after resection of pGB indicates that the results obtained can become an effective tool for predicting survival in this group of patients.
Keywords: brain glioblastoma, ASL perfusion magnetic resonance imaging, residual glioblastoma, hyperperfusion focus, survival, radiation therapy
For citation: Rozanov ID, Bunak MS, Glazkov AA, Stepanova EA, Lebedev SS, Balkanov AS. Postoperative Perfusion Magnetic Resonance Imaging as a Tool for Predicting Survival in Glioblastoma of the Brain. Medical Radiology and Radiation Safety. 2022;67(6):67–73. (In Russian). DOI:10.33266/1024-6177-2022-67-6-67-73
References
1. Ostrom Q.T., Cote D.J., Ascha M., Kruchko C., Barnholtz-Sloan J.S. Adult Glioma Incidence and Survival by Race or Ethnicity in the United States from 2000 to 2014. JAMA Oncol. 2018;4;9:1254-1262. doi: 10.1001/jamaoncol.2018.1789.
2. Amirian E.S., Armstrong G.N., Zhou R., Lau C.C., Claus E.B., Barnholtz-Sloan J.S., Il’yasova D., Schildkraut J., Ali-Osman F., Sadetzki S., Johansen C., Houlston R.S, Jenkins R.B., Lachance D.,. Olson S.H., Bernstein J.L., Merrell R.T., Wrensch M.R., Davis F.G., Lai R., Shete S., Amos C.I., Scheurer M.E., Alafuzoff K.I., Brännström T., Broholm H., Collins P., Giannini C., Rosenblum M., Tihan T., Melin B.S., Bondy M.L. The Glioma International Case-control Study: A Report From the Genetic Epidemiology of Glioma International Consortium. Am. J. Epidemiol. 2016;183;2:85-91.
3. Chaichana K.L., Jusue-Torres I., Navarro-Ramirez R., Raza S.M., Pascual-Gallego M., Ibrahim A., Hernandez-Hermann M., Gomez L., Ye X., Weingart J.D., Olivi A., Blakeley J., Gallia G.L., Lim M., Brem H., Quinones-Hinojosa A. Establishing Percent Resection and Residual Volume Thresholds Affecting Survival and Recurrence for Patients with Newly Diagnosed Intracranial Glioblastoma. Neuro Oncol. 2014;16;1:113-122. doi: 10.1093/neuonc/not137.
4. Wen P.Y., Weller M., Lee E.Q., et al. Glioblastoma in Adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. Neuro Oncol. 2020;22;8:1073-1113. doi:10.1093/neuonc/noaa106.
5. Burth S., Kickingereder P., Eidel O., Tichy D., Bonekamp D., Weberling L., Wick A., Löw S., Hertenstein A., Nowosielski M., Schlemmer H.P., Wick W., Bendszus M., Radbruch A. Clinical Parameters Outweigh Diffusion- and Perfusion-Derived MRI Parameters in Predicting Survival in Newly Diagnosed Glioblastoma. Neuro Oncol. 2016;18;12:1673-1679. doi: 10.1093/neuonc/now122.
6. Molinaro A.M., Hervey-Jumper S., Morshed R.A., Young J., Han S.J., Chunduru P., Zhang Y., Phillips J.J., Shai A., Lafontaine M., Crane J., Chandra A., Flanigan P., Jahangiri A., Cioffi G., Ostrom Q., Anderson J.E., Badve C., Barnholtz-Sloan J., Sloan A.E., Erickson B.J., Decker P.A., Kosel M.L., LaChance D., Eckel-Passow J., Jenkins R., Villanueva-Meyer J., Rice T., Wrensch M., Wiencke J.K., Oberheim Bush N.A., Taylor J., Butowski N., Prados M., Clarke J., Chang S., Chang E., Aghi M., Theodosopoulos P., McDermott M., Berger M.S. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor with Survival Within Molecular Subgroups of Patients with Newly Diagnosed Glioblastoma. JAMA Oncol. 2020;6;4:495-503. doi: 10.1001/jamaoncol.2019.6143. Erratum in: JAMA Oncol. 2020;6;3:444.
7. Kasper J., Hilbert N., Wende T., Fehrenbach M.K., Wilhelmy F., Jähne K., Frydrychowicz C., Hamerla G., Meixensberger J., Arlt F. On the Prognosis of Multifocal Glioblastoma: An Evaluation Incorporating Volumetric MRI. Curr Oncol. 2021;28;2:1437-1446. doi: 10.3390/curroncol28020136.
8. Ma R., Chari A., Brennan P.M., Alalade A., Anderson I., Solth A., Marcus H.J., Watts C., British Neurosurgical Trainee Research Collaborative. Residual Enhancing Disease after Surgery for Glioblastoma: Evaluation of Practice in the United Kingdom. Neurooncol Pract. 2018;5;2:74-81. doi: 10.1093/nop/npx023.
9. Wang P., Li J., Diao Q., Lin Y., Zhang J., Li L., Yang G., Fang X., Li X., Chen Y., Zheng L., Lu G. Assessment of Glioma Response to Radiotherapy Using 3D Pulsed-Continuous Arterial Spin Labeling and 3D Segmented Volume. Eur. J. Radiol. 2016;85;11:1987-1992. doi: 10.1016/j.ejrad.2016.08.009.
10. Batalov A.I., Zakharova N.Ye., Pogosbekyan E.L., Fadeyeva L.M., Goryaynov S.A., Bayev A.A., Shults Ye.I., Chelushkin D.M., Potapov A.A., Pronin I.N. Non-Contrast ASL Perfusion in Preoperative Diagnosis of Supratentorial Gliomas. Zhurnal Voprosy Neyrokhirurgii Imeni N.N. Burdenko = Burdenko’s Journal of Neurosurgery. 2018;82;6:15‑22. DOI 10.17116/neiro20188206115.
11. Marl H., Ertekin E., Tunçyürek Ö., Özsunar Y. Effects of Susceptibility Artifacts on Perfusion MRI in Patients with Primary Brain Tumor: A Comparison of Arterial Spin-Labeling versus DSC. AJNR Am. J. Neuroradiol. 2020;41;2:255-261. doi: 10.3174/ajnr.A6384.
12. Soni N., Dhanota D.P.S., Kumar S., Jaiswal A.K., Srivastava A.K. Perfusion MR Imaging of Enhancing Brain Tumors: Comparison of Arterial Spin Labeling Technique with Dynamic Susceptibility Contrast Technique. Neurol. India. 2017;65;5:1046-1052. doi: 10.4103/neuroindia.
13. Jovanovic M., Radenkovic S., Stosic-Opincal T., Lavrnic S., Gavrilovic S., Lazovic-Popovic B., Soldatovic I., Maksimovic R. Differentiation between Progression and Pseudoprogresion by Arterial Spin Labeling MRI in Patients with Glioblastoma Multiforme. J. BUON. 2017;22;4:1061-1067.
14. Xu Q., Liu Q., Ge H., Ge X., Wu J., Qu J., Xu K. Tumor Recurrence Versus Treatment Effects in Glioma: A Comparative Study of three Dimensional Pseudo-Continuous Arterial Spin Labeling and Dynamic Susceptibility Contrast Imaging. Medicine (Baltimore). 2017;96;50:e9332. doi: 10.1097/MD.0000000000009332.
15. Lindner T., Ahmeti H., Lübbing I., Helle M., Jansen O., Synowitz M., Ulmer S. Intraoperative Resection Control Using Arterial Spin Labeling - Proof of Concept, Reproducibility of Data and Initial Results. Neuroimage Clin. 2017;15:136-142. doi: 10.1016/j.nicl.2017.04.021.
16. Rebrikova V.A., Sergeev N.I., Padalko B.V., Kotlyarov P.M., Solodkiy V.A. The Use of Mr Perfusion in Assessing the Efficacy of Treatment for Malignant Brain Tumors. Zhurnal Voprosy Neyrokhirurgii Imeni N.N. Burdenko = Burdenko’s Journal of Neurosurgery. 2019;83;4:113-120 (In Russ.).
17. Kotlyarov P.M., Nudnov N.V., Vinikovetskaya A.V., Egorova E.V., Albitskiy I.A., Ovchinnikov V.I., Gombolevskiy V.A. Ct Perfusion in Diagnostic and Estimation Treatment Efficacy of Malignant Cranial Gliomas. Luchevaya Diagnostika i Terapiya = Diagnostic Radiology and Radiotherapy. 2015;2:63-69. (In Russ.).
18. Brown T.J., Brennan M.C., Li M., Church E.W., Brandmeir N.J., Rakszawski K.L., Patel A.S., Rizk E.B., Suki D., Sawaya R., Glantz M. Association of the Extent of Resection with Survival in Glioblastoma: A Systematic Review and Meta-Analysis. JAMA Oncol. 2016;2;11:1460-1469. doi: 10.1001/jamaoncol.2016.1373.
19. Garcia-Ruiz A., Naval-Baudin P., Ligero M., Pons-Escoda A., Bruna J., Plans G., Calvo N., Cos M., Majós C., Perez-Lopez R. Precise Enhancement Quantification in Post-Operative MRI as an Indicator of Residual Tumor Impact Is Associated with Survival in Patients with Glioblastoma. Sci Rep. 2021;11;1:695. doi: 10.1038/s41598-020-79829-3.
20. Laurent D., Freedman R., Cope L., Sacks P., Abbatematteo J., Kubilis P., Bova F., Rahman M. Impact of Extent of Resection on Incidence of Postoperative Complications in Patients with Glioblastoma. Neurosurgery. 2020;86;5:625-630. doi: 10.1093/neuros/nyz313.
21. Khashbat D., Harada M., Abe T., Ganbold M., Iwamoto S., Uyama N., Irahara S., Otomi Y., Kageji T., Nagahiro S. Diagnostic Performance of Arterial Spin Labeling for Grading Nonenhancing Astrocytic Tumors. Magn. Reson. Med. Sci. 2018;17;4:277-282. doi: 10.2463/mrms.mp.2017-0065.
22. Zeng Q., Jiang B., Shi F., Ling C., Dong F., Zhang J. 3D Pseudocontinuous Arterial Spin-Labeling MR Imaging in the Preoperative Evaluation of Gliomas. AJNR Am. J. Neuroradiol. 2017;38;10:1876-1883. doi: 10.3174/ajnr.A5299.
23. Falk Delgado A., De Luca F., van Westen D., Falk Delgado A. Arterial Spin Labeling MR Imaging for Differentiation between High- and Low-Grade Glioma-a Meta-Analysis. Neuro Oncol. 2018;20;11:1450-1461. doi:10.1093/neuonc/noy095.
24. Bag A.K., Cezayirli P.C., Davenport J.J., et al. Survival Analysis in Patients with Newly Diagnosed Primary Glioblastoma Multiforme Using Pre- and Post-Treatment Peritumoral Perfusion Imaging Parameters. J. Neurooncol. 2014;120;2:361‐370. doi:10.1007/s11060-014-1560-9.
25. Bunak M.S., Stepanova YE.A., Stashuk G.A. The Potentiality of Arterial Spins Labeling (ASL) Magnetic Resonance Perfusion Technique for the Diagnosis of Glioblastoma Residual Tissue. Almanakh Klinicheskoy Meditsiny = Almanac of Clinical Medicine. 2021;49;1:41–48. doi: 10.18786/2072-0505-2021-49-012 (In Russ.).
26. Kumar N., Kumar R., Sharma S.C., Mukherjee A., Khandelwal N., Tripathi M., Miriyala R., Oinam A.S., Madan R., Yadav B.S., Khosla D., Kapoor R. Impact of Volume of Irradiation on Survival and Quality of Life in Glioblastoma: a Prospective, Phase 2, Randomized Comparison of RTOG and MDACC Protocols. Neurooncol Pract. 2020;7;1:86-93. doi: 10.1093/nop/npz024.
27. Ali M.Y., Oliva C.R., Noman A.S.M., Allen B.G., Goswami P.C., Zakharia Y., Monga V., Spitz D.R., Buatti J.M., Griguer C.E. Radioresistance in Glioblastoma and the Development of Radiosensitizers. Cancers (Basel). 2020;12;9:2511. doi: 10.3390/cancers12092511.
28. Simpson J.R., Horton J., Scott C., Curran W.J., Rubin P., Fischbach J., Isaacson S., Rotman M., Asbell S.O., Nelson J.S., et al. Influence of Location and Extent of Surgical Resection on Survival of Patients with Glioblastoma Multiforme: Results of Three Consecutive Radiation Therapy Oncology Group (RTOG) Clinical Trials. Int. J. Radiat. Oncol. Biol. Phys. 1993;26;2:239-44. doi: 10.1016/0360-3016(93)90203-8.
29. Al-Holou W.N., Hodges T.R., Everson R.G., Freeman J., Zhou S., Suki D., Rao G., Ferguson S.D., Heimberger A.B., McCutcheon I.E., Prabhu S.S., Lang F.F., Weinberg J.S., Wildrick D.M., Sawaya R. Perilesional Resection of Glioblastoma Is Independently Associated With Improved Outcomes. Neurosurgery. 2020;86;1:112-121. doi: 10.1093/neuros/nyz008.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.07.2022. Accepted for publication: 25.09.2022.